Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes
Completed · Phase 4
Conditions studied: Hypertension, Type 2 Diabetes Mellitus
In brief
The purpose of this study is to compare the vascular effects of two commonly used blood pressure medications, carvedilol and metoprolol in hypertensive patients with type 2 diabetes.
Key facts
- Study ID
- NCT00123604
- Run by
- St. Paul Heart Clinic
- People needed
- 36
- Starts
- 2004-06-01
- Expected to finish
- 2006-06-01
- Last updated by the study team
- 2014-11-18
Who can join
Age: 30 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age 30-80 years old
- Documented history of type 2 diabetes
- Stable angiotensin converting enzyme/angiotensin receptor blocker (ACE/ARB) regimen 30 days before and throughout the study period
- Stable anti-diabetic regimen throughout the study period
- Body mass index (BMI) between 22-45 kg/m2
- HbA1c between 6-9% for patients on anti-diabetic treatment regimen and HbA1c between 6-8% for patients who are being controlled by diet alone
- Screening blood pressure (BP) > 130/80 (average of 3 sitting measurements), with current medications
You may not qualify if…
- Uncontrollable or symptomatic arrhythmias
- Unstable angina
- Sick sinus syndrome or second or third degree heart block
- Decompensated heart failure
- Myocardial infarction (MI) or stroke within 3 months of screening
- Bradycardia
- Chronic obstructive pulmonary disease (COPD) with required inhaled or oral bronchodilators or corticosteroids
- Bronchial asthma or related bronchospastic conditions
- New onset/diagnosed type 2 diabetes (<3 months)
- Clinically significant renal or liver disease (creatinine >2.5 mg/dL)
- Endocrine disorders
- Use of anorectic or other diet drugs inconsistent with recommendations for type 2 diabetics
- Use of beta-blockers within 3 months of screening
- Use of corticosteroids
- Systemic disease, including cancer, with reduced life expectancy (<12 months)
- Psychological illness/condition that interferes with comprehension of study requirements
- Use of an investigational drug within 30 days of entry into study
Where it is running
- St. Paul Heart Clinic — Saint Paul, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.